Nitisinone Dipharma (Nitisinone)

Nitisinone blocks the enzyme p‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine catabolic pathway. This inhibition stops the formation of downstream toxic compounds such as maleylacetoacetate and fumarylacetoacetate, thereby lowering the risk of liver and kidney damage associated with the disorder.

The specific dose of Nitisinone Dipharma is determined by the prescribing physician based on the patient’s age, weight, disease severity, and laboratory monitoring results. Dosage adjustments may be required during treatment, and the prescriber will provide individualized instructions.

Safety data for Nitisinone in pregnancy and lactation are limited. The potential risk to the fetus or infant is not well established, so the drug should only be used if the potential benefit justifies the possible risk. Women of child‑bearing potential should discuss contraception and treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nitisinone is the primary disease‑modifying therapy for hereditary tyrosinemia type I, directly targeting the metabolic defect. Alternative approaches, such as liver transplantation, address end‑stage organ damage but do not correct the underlying metabolic pathway. Nitisinone therefore offers a less invasive, long‑term management option when initiated early.

Nitisinone Dipharma should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Nitisinone Dipharma is taken orally, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include hepatic dysfunction, which may manifest as elevated liver enzymes or liver injury, and rare severe allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of liver toxicity and any hypersensitivity symptoms, and treatment should be discontinued if serious adverse events occur.

Nitisinone Dipharma should be avoided in individuals with known hypersensitivity to nitisinone or any of its excipients. Caution is also advised for patients with severe hepatic impairment, and the drug should only be used in pregnancy or lactation when the potential benefits outweigh the risks.